WO2002026776A3 - Composés à base de peptides - Google Patents

Composés à base de peptides Download PDF

Info

Publication number
WO2002026776A3
WO2002026776A3 PCT/NO2001/000390 NO0100390W WO0226776A3 WO 2002026776 A3 WO2002026776 A3 WO 2002026776A3 NO 0100390 W NO0100390 W NO 0100390W WO 0226776 A3 WO0226776 A3 WO 0226776A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
peptide
based compounds
relates
compounds
Prior art date
Application number
PCT/NO2001/000390
Other languages
English (en)
Other versions
WO2002026776A2 (fr
Inventor
Alan Cuthbertson
Original Assignee
Amersham Health As
Alan Cuthbertson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002531159A priority Critical patent/JP4948742B2/ja
Priority to KR1020037004291A priority patent/KR100896983B1/ko
Priority to CA002420577A priority patent/CA2420577A1/fr
Priority to EP01972816A priority patent/EP1358206B1/fr
Priority to AU2001292456A priority patent/AU2001292456B2/en
Priority to AU9245601A priority patent/AU9245601A/xx
Application filed by Amersham Health As, Alan Cuthbertson filed Critical Amersham Health As
Priority to AT01972816T priority patent/ATE519776T1/de
Publication of WO2002026776A2 publication Critical patent/WO2002026776A2/fr
Priority to NO20031323A priority patent/NO331535B1/no
Priority to US10/395,500 priority patent/US7737252B2/en
Publication of WO2002026776A3 publication Critical patent/WO2002026776A3/fr
Priority to US12/814,621 priority patent/US8258101B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne de nouveaux composés à base de peptides et leur utilisation dans des traitements thérapeutiquement efficaces, ainsi que dans des techniques d'imagerie diagnostique. Plus spécialement, l'invention concerne l'utilisation de ces composés comme vecteurs de ciblage qui se lient à des récepteurs associés à l'angiogénèse, en particulier le récepteur de l'intégrine αvβ3. Ces agents de contraste peuvent ainsi être utilisés dans le diagnostique, par exemple, de maladies malignes, des maladies cardiaques, des maladies liées à une inflammation, l'arthrite rhumatoïde et le sarcome de Kaposi. Ces composés peuvent, en outre, être utilisés dans le traitement thérapeutique de ces maladies.
PCT/NO2001/000390 2000-09-26 2001-09-25 Composés à base de peptides WO2002026776A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020037004291A KR100896983B1 (ko) 2000-09-26 2001-09-25 펩티드-기재 화합물
CA002420577A CA2420577A1 (fr) 2000-09-26 2001-09-25 Composes a base de peptides
EP01972816A EP1358206B1 (fr) 2000-09-26 2001-09-25 Composes a base de peptides
AU2001292456A AU2001292456B2 (en) 2000-09-26 2001-09-25 Peptide-based compounds
AU9245601A AU9245601A (en) 2000-09-26 2001-09-25 Peptide-based compounds
JP2002531159A JP4948742B2 (ja) 2000-09-26 2001-09-25 ペプチド系化合物
AT01972816T ATE519776T1 (de) 2000-09-26 2001-09-25 Peptidische verbindungen
NO20031323A NO331535B1 (no) 2000-09-26 2003-03-24 Peptidbaserte forbindelser, fremgangsmate for fremstilling og farmasoytiske sammensetninger omfattende slike, samt anvendelse.
US10/395,500 US7737252B2 (en) 2000-09-26 2003-03-24 Peptide-based compounds
US12/814,621 US8258101B2 (en) 2000-09-26 2010-06-14 Peptide-based compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20004795 2000-09-26
NO20004795A NO20004795D0 (no) 2000-09-26 2000-09-26 Peptidbaserte forbindelser
US25991901P 2001-01-05 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/395,500 Continuation US7737252B2 (en) 2000-09-26 2003-03-24 Peptide-based compounds

Publications (2)

Publication Number Publication Date
WO2002026776A2 WO2002026776A2 (fr) 2002-04-04
WO2002026776A3 true WO2002026776A3 (fr) 2003-08-28

Family

ID=19911612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2001/000390 WO2002026776A2 (fr) 2000-09-26 2001-09-25 Composés à base de peptides

Country Status (10)

Country Link
US (2) US7737252B2 (fr)
EP (1) EP1358206B1 (fr)
JP (1) JP4948742B2 (fr)
KR (1) KR100896983B1 (fr)
CN (2) CN1462276A (fr)
AT (1) ATE519776T1 (fr)
AU (2) AU9245601A (fr)
CA (1) CA2420577A1 (fr)
NO (2) NO20004795D0 (fr)
WO (1) WO2002026776A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
AU2002248297A1 (en) * 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
RU2303042C2 (ru) 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
WO2004043396A2 (fr) * 2002-11-09 2004-05-27 Nobex Corporation Promedicaments contenant du carbamate modifie et methodes de synthese de ces derniers
EP1481683A1 (fr) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Ligands ayant pour cible la P-selectine et compositions les comprenant
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
NO20035748D0 (no) * 2003-12-19 2003-12-19 Amersham Health As Optisk avbildning av sårbar arteriosklerose
RU2007118385A (ru) * 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
WO2006073314A1 (fr) * 2005-01-06 2006-07-13 Ge Healthcare As Imagerie optique
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
EP2056886A2 (fr) * 2006-08-28 2009-05-13 GE Healthcare Limited Produits radiopharmaceutiques à base de peptides étiquetés 68ga
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
KR101016214B1 (ko) * 2007-04-23 2011-02-25 한국과학기술연구원 근적외선 형광체가 결합된 담즙산-글라이콜키토산 복합체나노입자를 포함하는 류마티스 관절염 진단용 조영제
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
AU2014396468B2 (en) * 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof
EP3037820A1 (fr) * 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Procédé de détection de cellules et réactifs ayant un groupe fonctionnel d'étiquetage libérable
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015818A1 (fr) * 1989-06-19 1990-12-27 Antisoma Limited Peptides synthetiques destines a la detection des thrombus
WO1995014714A1 (fr) * 1993-11-24 1995-06-01 La Jolla Cancer Research Foundation Nouveaux peptides fixant l'integrine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
SE463651B (sv) 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
EP0466200B1 (fr) 1987-07-16 1996-04-24 Nycomed Imaging As Acides aminocarboxyliques et dérivés
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
GB9007408D0 (en) 1990-04-02 1990-05-30 Nycomed As Compositions
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9120508D0 (en) 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
FR2699595B1 (fr) * 1992-12-23 1995-01-20 Snecma Dispositif de guidage en rotation d'un anneau de commande d'aubes pivotantes.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2185810A1 (fr) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU687093B2 (en) 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
AU726793B2 (en) 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
DE69637395T2 (de) 1995-09-11 2008-12-18 La Jolla Cancer Research Foundation, La Jolla Moleküle, die sich in ausgewählten Organen oder Geweben in-vivo einfinden
PL327679A1 (en) 1996-01-10 1998-12-21 Nycomed Imaging As Contast medium
WO1997028830A1 (fr) 1996-02-09 1997-08-14 Steinel Gmbh & Co. Kg Dispositif de vaporisation d'une substance liquide
WO1997029783A1 (fr) 1996-02-19 1997-08-21 Nycomed Imaging A/S Perfectionnements relatifs aux milieux de contraste
DE69734887T2 (de) 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
GB9624918D0 (en) 1996-11-29 1997-01-15 Nycomed Imaging As Particulate components
CA2291323A1 (fr) 1997-05-28 1998-12-03 Genvec, Inc. Adenovirus a ciblage alternatif
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
WO1999039734A1 (fr) 1998-02-06 1999-08-12 The Uab Research Foundation Vecteur adenoviral contenant un epitope peptidique heterologue dans la boucle hi du bouton de fibre
CA2318981A1 (fr) 1998-02-09 1999-08-12 Genzyme Corporation Vehicules d'apport d'acide nucleique
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
US6559279B1 (en) * 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015818A1 (fr) * 1989-06-19 1990-12-27 Antisoma Limited Peptides synthetiques destines a la detection des thrombus
WO1995014714A1 (fr) * 1993-11-24 1995-06-01 La Jolla Cancer Research Foundation Nouveaux peptides fixant l'integrine

Also Published As

Publication number Publication date
NO331535B1 (no) 2012-01-23
NO20031323L (no) 2003-03-24
JP2004509975A (ja) 2004-04-02
US20030176639A1 (en) 2003-09-18
AU2001292456B2 (en) 2008-02-28
US20100256330A1 (en) 2010-10-07
EP1358206B1 (fr) 2011-08-10
NO20004795D0 (no) 2000-09-26
ATE519776T1 (de) 2011-08-15
EP1358206A2 (fr) 2003-11-05
JP4948742B2 (ja) 2012-06-06
US8258101B2 (en) 2012-09-04
CA2420577A1 (fr) 2002-04-04
KR100896983B1 (ko) 2009-05-14
CN101531704A (zh) 2009-09-16
KR20030061811A (ko) 2003-07-22
WO2002026776A2 (fr) 2002-04-04
US7737252B2 (en) 2010-06-15
CN1462276A (zh) 2003-12-17
AU9245601A (en) 2002-04-08
NO20031323D0 (no) 2003-03-24

Similar Documents

Publication Publication Date Title
WO2002026776A3 (fr) Composés à base de peptides
SI1648925T1 (sl) Biciklična peptidna kontrastna sredstva
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
MXPA04000173A (es) Compuestos basados en peptidos.
WO2003057838A3 (fr) Anticorps contre l&#39;antigene muc18
WO2003057006A3 (fr) Utilisation d&#39;anticorps diriges contre l&#39;antigene muc18
WO1999017755A3 (fr) Medicaments
WO2003057837A8 (fr) Procedes d&#39;utilisation d&#39;anticorps anti-muc18
EP2292649A3 (fr) Epitopes thérapeutiques et leurs utilisations
NZ521735A (en) Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NZ522326A (en) Adenosine A2A receptor antagonists
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer&#39;s disease
WO2001097860A3 (fr) Produits pharmaceutiques pour l&#39;imagerie de troubles angiogeniques
DE69720241T2 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
WO1999051186A3 (fr) Procedes et compositions destines au diagnostic et au traitement de troubles neuropsychiatriques
WO2002046221A3 (fr) Proteines
EP1293214A3 (fr) Antagonistes du LTB4 et produits radiopharmaceutiques pour l&#39;imagerie de l&#39;infection et l&#39;inflammation
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
WO2008072973A3 (fr) Composés à base de peptides marqués radioactivement et leurs utilisations
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2420577

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001292456

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001972816

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018161308

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10395500

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020037004291

Country of ref document: KR

Ref document number: 2002531159

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037004291

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001972816

Country of ref document: EP